GRI Bio Inc.
0.74
0.01 (1.37%)
At close: Jan 14, 2025, 3:59 PM
0.70
-5.17%
After-hours Jan 14, 2025, 04:12 PM EST
undefined%
Bid 0.71
Market Cap 6.61M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 77.53
PE Ratio (ttm) 0.01
Forward PE n/a
Analyst Buy
Ask 0.75
Volume 178,577
Avg. Volume (20D) 4,163,708
Open 0.74
Previous Close 0.73
Day's Range 0.72 - 0.76
52-Week Range 0.30 - 65.00
Beta undefined

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sc...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GRI

Analyst Forecast

According to 2 analyst ratings, the average rating for GRI stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 1453.21% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-19.57%
GRI Bio shares are trading lower after the company... Unlock content with Pro Subscription
3 months ago · Source
+25.43%
GRI Bio shares are trading higher after the company announced it presented preclinical data highlighting GRI-0621's ability to inhibit invariant natural killer T cell activity.